124 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
on our Board of Directors since November 2022. Mr. Yoskowitz is Chief Executive Officer of Evozyne, Inc. Previously he served as EVP and Chief Strategy … initiatives within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira and was a member
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation for the treatment of AATD-LD.
Our strategy is to selectively acquire … on this strategy by acquiring six clinical-stage product candidates of which four were in rare diseases and oncology. Four of our six clinical-stage
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
and information, including study designs and protocols, reagents and biological methodology, any strategy for the prosecution, maintenance, enforcement and defense
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
strategy for Phase 3. The pivotal Phase 3 portion of the study will include approximately 195 patients at 50 sites across 12 countries, randomized 2:1 … .
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
and capital allocation strategy. This review included a detailed evaluation of current market conditions, the status of our ongoing programs
6-K
EX-99.1
f67kp8v
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
u876c grpgh0s3mi8u5b
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
54u0lsb42l
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
o1bzemqzazbh0q
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
l46cwn2lw2yqhl
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
6mhmr6qe2k
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
pspjg
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
0evyytz1lf7j574qdcs
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
EX-99.1
vp7b6ynzjotq5
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
mg8ji30usnv86d37pnbk
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
j60qpkb1 sm7hmg
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
6-K
EX-99.1
nf7f1rr
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
6-K
m93f 9i7az
17 May 22
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
8:19am
6-K
EX-99.1
3o3im41p 2bqo3t
17 May 22
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
8:19am
6-K
EX-99.1
reg mhvprhl76nvqv
9 May 22
Current report (foreign)
8:06am